StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Thursday. The firm issued a sell rating on the stock.

VNRX has been the topic of several other research reports. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research note on Wednesday, March 12th.

VolitionRx Price Performance

Shares of VNRX opened at $0.55 on Thursday. The stock’s 50-day moving average is $0.60 and its two-hundred day moving average is $0.64. The stock has a market cap of $50.97 million, a PE ratio of -1.53 and a beta of 1.09. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.02.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Two Sigma Securities LLC acquired a new stake in VolitionRx during the fourth quarter valued at approximately $29,000. Millennium Management LLC acquired a new stake in VolitionRx during the fourth quarter valued at approximately $36,000. Northern Trust Corp raised its stake in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares in the last quarter. Geode Capital Management LLC raised its stake in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after buying an additional 95,900 shares in the last quarter. Finally, Lagoda Investment Management L.P. raised its stake in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.